An Overview of the CALGB 40101 Trial in Breast Cancer
Lawrence N. Shulman, MD,discusses the results of the CALGB 40101 trial.
Lawrence N. Shulman, MD, chief of staff, senior vice president for medical affairs, director, Center for Global Cancer Medicine, director, Department of Regional Strategy and Development, chief, Division of General Oncology, Dana-Farber Cancer Institute, discusses the results of the CALGB 40101 trial.
Clinical Pearls
- The CALGB 40101 trial looked at patients who had 0-3 positive axillary nodes and 90% of the patients enrolled in the trial had node-negative disease
- The trial compared standard chemotherapy (adjuvant cyclophosphamide (AC) and doxorubicin) versus paclitaxel. Patients received 6 cycles or 4 cycles of either treatment
- The trial showed that 6 cycles of therapy was not superior to 4 cycles of therapy in any of the subgroups and that paclitaxel was not equivalent to AC
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
